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Abstract: A ruthenium(II)–arene complex with picolinic acid, [(η6-p-cyme-
ne)RuCl(pico)]·H2O, was prepared by the reaction of [(η6-p-cymene)RuCl2]2 
with picolinic acid in a 1:2 molar ratio in 2-propanol. The compound was cha-
racterized by elemental analysis, and IR and NMR spectroscopy. X-ray diffrac-
tion analysis showed that the molecule adopts a “three-leg piano-stool” geo-
metry, which is common for this type of complexes. The cytotoxic activity of 
the complex was tested in two human cancer cell lines HeLa (cervix) and FemX 
(melanoma) by MTT assay. The IC50 values were at 82.0 and 36.2 µmol dm-3 
for HeLa and FemX cells, respectively. 
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INTRODUCTION 
The structures and chemical properties of metal complexes of some pyridine 
carboxylates have been widely investigated.1–5 Picolinic acid (2-pyridinecar-
boxylic acid) is a biologically important ligand incorporated into some enzymes, 
and it is an active agent in some drugs as well.6–11 It is also catabolite of L-tryp-
tophan detected in the human body.12,13 Picolinates are used as dietary supple-
ments. In particular, the chromium(III) complex reduces diabetes risk and there-
fore is used as a dietary supplement for obese people.14 Zinc picolinate revealed 
an effect in the oxidant–antioxidant balance in patients with chronic obstructive 
pulmonary disease.15 Alkaline picolinates inhibit the growth of Escherichia 
coli.16,17 Platinum complexes with picolinic acid have been synthesized and 
screened for cytotoxic activity.18 
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In recent years, ruthenium complexes have gained much attention19–23 in at-
tempts to overcome the downsides of platinum complexes. Organometallic com-
plexes and half-sandwich complexes of Ru(II) emerged as promising scaffolds 
for anticancer drug design.24–35 They often show aqueous solubility along with 
the necessary lipophilicity. The electronic system of the arene ligand stabilizes 
the metal in its lower oxidation state and also provides a hydrophobic face in the 
complex, which might enhance transport of ruthenium through cell membranes. 
In addition, ruthenium compounds possess good cytotoxic activity, while not no-
tably affecting normal cells.36,37 One aspect of the action of ruthenium com-
plexes is their ability to bind with the serum proteins: transferrin and albumin.38 
Tumor cells are more susceptible to ruthenium complexes due to an increased de-
mand for iron and therefore there is an increased number of transferrin receptors 
on their surface.39,40 In addition, because ruthenium can mimic iron in binding to 
carrier proteins, its excess can be removed from cells, which is the reason for 
lower toxicity of ruthenium complexes compared to platinum complexes.39  
Recently, two series of Ru(II)-arene complexes with functionalized pyridines 
were described of the general formulae [(η6-p-cymene)Ru(XY)Cl] and [(η6-p- 
-cymene)Ru(X)Cl2], where XY were the mono-anionic N,O-bidentates 2,3-
pyridine-, 2,4-pyridine-, 2,5-pyridine- and 2,6-pyridine-dicarboxylate, while X 
were monodentate ligands 3-acetylpyridine, 4-acetylpyridine, 2-amino-5-chlo-
ropyridine, isonicotinic or nicotinic acid bound to ruthenium(II) via the pyridine 
nitrogen.41 
Herein the X-ray diffraction structure of [(η6-p-cymene)Ru(pico)Cl] and its 
antiproliferative activity in two human cancer cell lines (cervix HeLa and mela-
noma Femx) are reported. Since the introduction of picolinate into a metal com-
plex can result in enhanced activity,42,43 the aim of this work was to compare the 
activities of the prepared complex with previously described analogue com-
plexes.41 It should be noted that the complex was previously described but its X-
ray diffraction structure has not hitherto been reported.44 
EXPERIMENTAL 
Materials and measurements 
Picolinic acid was purchased from Acros Organics and used without further purification. 
[(η6-p-Cymene)RuCl2]2 was prepared according to a published procedure.45 Elemental anal-
ysis was realized using an Elemental Vario EL III microanalyzer. The infrared spectra were 
recorded on a Nicolet 6700 FT-IR spectrometer using the attenuated total reflectance (ATR) 
technique. The 1H- and 13C-NMR spectra of the ligand and the complex were recorded on a 
Varian Gemini 200 instrument. Chemical shifts were referenced to residual 1H and 13C pre-
sent in deuterated dimethyl sulfoxide. 
Synthesis of the complex 
To a warm solution of [(η6-p-cymene)RuCl2]2 (0.100 g, 0.16 mmol) in 2-propanol (25 
cm3) was added a solution of picolinic acid (0.046 g, 0.35 mmol) in 2-propanol (5 cm3). The 
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mixture was stirred at room temperature for 7 days and then kept in refrigerator until the 
product precipitated. The yellow-orange product was filtered off, washed with several drops 
of 2-propanol and then diethyl ether and dried in air. A crystal suitable for X-ray analysis was 
obtained by the slow evaporation of the mother liquor.  
Crystallographic structure determination 
The measurement was performed on a Bruker X8 APEXII CCD diffractometer. A single 
crystal was positioned at 35 mm from the detector and 941 frames were measured, each for 30 s 
over a 1° scan width. The data were processed using SAINT-Plus software.46 The crystal data, 
data collection parameters and structure refinement details are given in Table I. The structure 
was solved by direct methods and refined by full-matrix least-squares techniques. Non-hyd-
rogen atoms were refined with anisotropic displacement parameters. The H atoms were placed 
at calculated positions and refined as riding atoms in the subsequent least-squares model re-
finements. The isotropic thermal parameters were estimated to be 1.2 or 1.5 times (methyl 
groups) the values of the equivalent isotropic thermal parameters of the non-hydrogen atoms 
to which the hydrogen atoms were bonded. The following software programs, personal 
computer and tables were used: structure solution, SHELXS-97,47 refinement, SHELXL-97,48 
molecular diagrams, ORTEP,49 Pentium IV, Tables 4.2.6.8 and 6.1.1.4 for the scattering fac-
tors were taken from the literature.50 
TABLE I. Crystal data and details of data collection for 1·H2O 
Empirical formula C16H20ClNO3Ru 
FW 410.85 
Space group Pn
a / Å 8.9150(4) 
b / Å 8.6498(4) 
c / Å 10.6539(4) 
β / ° 91.853(3) 
V / Å3 821.12(6) 
Z 2 
λ / Å 0.71073 
ρcalcd / g cm–3 1.662 
Crystal size, mm3 0.50×0.05×0.01 
T / K 100 




aR1 = Σ||Fo| − |Fc||/Σ|Fo|; 
bwR2 = {Σ[w(Fo2 − Fc2)2]/Σ[w(Fo2)2]}1/2; 
cGOF = {Σ[w(Fo2 − Fc2)2]/(n − p)}1/2, where n 
is the number of reflections and p is the total number of parameters refined. 
Cytotoxicity 
Cell culture. Human cervix carcinoma cells (HeLa) and human melanoma cells (FemX) 
were maintained as monolayer cultures in Roswell Park Memorial Institute (RPMI) 1640 
nutrient medium (Sigma Chemicals Co, USA). The RPMI 1640 nutrient medium was prepa-
red in sterile deionized water, supplemented with penicillin (192 U ml-1), streptomycin (200 
μg ml-1), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) (25 mM), L-glutamine 
(3 mM) and 10 % heat-inactivated fetal calf serum (FCS) (pH 7.2). The cells were grown at 
37 °C in a 5 % CO2 humidified air atmosphere. 
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Cytotoxicity assay. The drug-induced cytotoxicity was determined using the 3-(4,5-dime-
thylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) assay.51 Cells were seeded in 
96-well cell culture plates (NUNC), HeLa (2000 c/w) and FemX (2000 c/w), in culture me-
dium and grown for 24 h. A stock solution of the complex was prepared in DMSO at a con-
centration of 30 mM and subsequently diluted with nutrient medium to the desired final con-
centrations (in the range up to 300 µM). 
Solutions of various concentrations of the examined compound were added to the wells, 
except for the control wells where only the nutrient medium was added. All samples were 
prepared in triplicate. Nutrient medium with corresponding agent concentrations but without 
the target cells was used as the blank, also in triplicate. The cells were incubated with the test 
compound for 48 h at 37 °C, in a 5 % CO2 humidified air atmosphere. After incubation, 20 µl 
of MTT solution, 5 mg mL-1 in phosphate buffer solution (PBS), pH 7.2, were added to each 
well. The samples were incubated for 4 h at 37 °C in a 5 % CO2 humidified air atmosphere. 
Formazan crystals were dissolved in 100 µL 10 % sodium dodecyl sulfate (SDS) in 0.01 M 
HCl. The absorbance was recorded on an enzyme-linked immunosorbent assay (ELISA) read-
er after 24 h at a wavelength of 570 nm. The IC50 (µM) was defined as the concentration of 
drug producing 50 % inhibition and was determined from cell survival diagrams. 
RESULTS AND DISCUSSION 
Synthesis 
The reaction of [(η6-p-cymene)RuCl2]2 with picolinic acid in a 1:2 molar 
ratio in 2-propanol at room temperature leads to the formation of the complex 
[(η6-p-cymene)RuCl(pico)]·H2O in high yield (Scheme 1). Crystals precipitated 
directly from the reaction mixture. The complex is soluble in water, methanol, 


















Scheme 1. Synthesis of the complex [(η6-p-cymene)RuCl(pico)]·H2O 
Analytic and spectral data 
Yield: 0.1 g, 76.9 %. Anal. Calcd. for C16H20O3NRuCl (Mr = 410.86): C, 
46.77; H, 4.91; N, 3.41 %. Found: C, 46.70; H, 4.98; N, 3.39. IR (ATR, cm–1): 
3536, 3467 (m), 3069, 2955 (w), 1637 (s), 1601 (w). 1H-NMR (199.97 MHz, 
DMSO-d6, δ / ppm): 1.12 (6H, dd, –CH(CH3)2, J = 2.2 and 7 Hz), 2.15 (3H, s, 
–CH3), 2.72 (1H, m, –CH(CH3)2, J = 6.8 Hz), 5.88 and 5.65 (4H, 2t, CH (arene), 
J = 4.6 and 7.8 Hz), 7.74 (1H, m, H4, J = 7.3 Hz), 7.79 (1H, m, H3), 8.09 (1H, td, 
H5, J = 7.5 Hz), 9.26 (1H, d, H6, J = 5.6 Hz). 13C-NMR (50.28 MHz, DMSO-d6, δ / 
/ ppm) 18.27 (CH3), 22.00 (CH(CH3)2), 30.65 (CH(CH3)2), 80.23, 81.21, 82.60, 
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82.78, 98.38 and 101.17 (CH (arene)), 125.59 (C3), 128.30 (C5), 139.86 (C4), 
150.73 (C2), 154.01 (C6), 170.70 (C1). 
Spectroscopy 
[(η6-p-Cymene)RuCl(pico)]·H2O exhibits an asymmetric stretching vibration 
νas(COO–) at 1637 cm−1. Picolinic acid revealed an analogous vibration of the 
free carboxylic group at 1718 cm−1. The difference in frequency is due to coor-
dination of the ligand through one of the oxygen atoms of the carboxylic group 
and nitrogen atom of the pyridine ring, and is consistent with the X-ray diffrac-
tion structure.  
The 1H NMR spectrum of the complex contains a characteristic pattern for 
the p-cymene moiety. A methyl group singlet is seen at 2.15 ppm, the resonance 
signal of –CH(CH3)2 appears as a multiplet at 2.72 ppm and -CH(CH3)2 as a 
doublet at 1.12 ppm. The resonances of the arene ring protons were found at 5.64 
and 5.88 ppm. Aromatic region of the 1H-NMR spectrum of the complex also 
shows four resonances (7.74 (1H), 7.78 (1H), 8.09 (1H), 9.26 (1H)) of coordi-
nated picolinate. Concerning the pyridine protons, H3 and H4 are shifted down-
field by 0.3 and 0.27 ppm, respectively, while H5 and H6 are shifted upfield by 
0.44 and 0.52 ppm, respectively, compared with the free ligand as a consequence 
of picolinate coordination to the ruthenium(II) atom. 
The 13C-NMR spectrum displays resonances at 18.27 ppm from the methyl 
group attached to the cymene moiety, 22.00 ppm from –CH(CH3)2, while the 
signal at 30.65 ppm is due to the CH(CH3)2 group. The aromatic carbons from 
cymene display resonances within 80.23–101.17 ppm. Five pyridine carbon reso-
nances were observed at 125.59 (C3), 128.30 (C5), 139.86 (C4), 150.73 (C2), 
154.01 (C6) and carboxylate carbon at 170.67 ppm (C1). 
X-Ray crystallography 
The structure of [(η6-p-cymene)RuCl(pico)]·H2O was confirmed by X-ray 
diffraction. The complex crystallized in the monoclinic space group Pn and has 
the typical “three-leg piano-stool” geometry well-documented for a large number 
of ruthenium(II) and osmium(II) arene complexes, and in particular, for the clo-
sely related compounds [(η6-1,3,5-Me3C6H3)RuCl(pico)]52 and [(η6-p-cyme-
ne)2OsCl(pico)],42 with the η6  π-bound arene ring forming the seat and the pico-
linate ligand bound via a nitrogen and one carboxylic oxygen, with one chloride 
ligand as the legs of the piano-stool. Selected bond lengths and angles are given 
in the legend to Fig. 1. The bond lengths Ru–ring centroid, Ru–Cl, Ru–O1 and Ru– 
–N1 in [(η6-p-cymene)RuIICl(pico)]·H2O of 1.665(9), 2.4225(9), 2.085(2) and 
2.101(3) Å, respectively, are slightly longer than similar bonds 1.652(2), 2.4048(13), 
2.080(3) and 2.090(4) Å in [(η6-p-cymene)OsIICl(pico)].42 The shortening of the 
Ru–N and Ru–O bonds in mer-[RuIII(pico)3]·H2O (2.052(3), 2.064(3), 2.052(3) 
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and 2.002(3), 2.024(3), 1.996(2) Å, respectively)53 is even more evident. The 
Ru–Cl, Ru–N1 and Ru–O1 bonds in [(η6-1,3,5-Me3C6H3)RuCl(pico)]52 are at 
2.420(1), 2.102(4) and 2.101(4) Å, respectively. Two hydrogen bonding interac-
tions between the co-crystallized water molecule and 1 of the type O3−H···O2 
(O3−H, 0.86, H···O2, 1.94, O3···O2, 2.78 Å, O3−H···O2, 168.5°) and O3−H···Cl1i 
(x + 0.5, −y + 1, z + 0.5) (O3−H, 0.87, H···O2, 1.94, O3···Cl1i, 2.78 Å, O3−H···Cl1i, 
172.6°) are evident in the crystal structure of 1·H2O. 
Fig. 1. ORTEP view of a molecule of 1 
with atom-labeling scheme and thermal 
ellipsoids drawn at the 50 % probabi-
lity level. Selected bond distances (Å) 
and angles (°): Ru−O1 2.085(2), Ru– 
–N1 2.101(3), Ru−Cl 2.4225(9), Ru– 
–C7 2.195(3), Ru−C8 2.186(3), Ru−C9 
2.175(4), Ru−C10 2.211(4), Ru−C11 
2.192(4) and Ru−C12 2.176(4), O1– 
–Ru−N1 77.96(10). 
Cytotoxic activity 
The antiproliferative activity of the prepared complex was assayed in two 
human cancer cell lines HeLa (cervix) and FemX (melanoma) by the MTT assay. 
The tumor cells were incubated for 48 h with the investigated complex. The re-
sults of these tests indicate that the complex after 48 h of incubation exhibited 
cytotoxic activity with IC50 81.97 µM for HeLa cells and 36.23 µM for FemX 
cells. These values are the mean of 2 to 3 independent experiments, whereby the 
standard deviations were less than 15 %. The results of representative experi-
ments are shown in Fig. 2. 
   
Fig. 2. Diagram of (a) HeLa and (b) FemX cells survival after 48 h of continual agent action. 
Data are representative for one out of two to three separate experiments 
with standard deviation. 
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CONCLUSIONS 
In this paper, the synthesis and characterization of the organoruthenium 
complex, [(η6-p-cymene)RuCl(pico)]·H2O is described. Although in a previous 
work, structurally related complexes were found to have limited antiproliferative 
activity in tumor cells, the complex reported herein exhibits much higher cyto-
toxicity in cervix HeLa and melanoma FemX human cancer cell lines. This im-
plies that the presence of picolinate coordinated to a metal center had a notable 
effect on cytotoxic activity. This makes this new ruthenium complex of interest 
for further investigation. 
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И З В О Д  
РЕНДГЕНСКА СТРУКТУРНА АНАЛИЗА И ЦИТОТОКСИЧНА АКТИВНОСТ 
ПИКОЛИНАТО РУТЕНИЈУМ(II)–АРЕНСКОГ КОМПЛЕКСА 
ИВАНКА ИВАНОВИЋ1, САЊА ГРГУРИЋ-ШИПКА1, НЕВЕНКА ГЛИГОРИЈЕВИЋ2, СИНИША РАДУЛОВИЋ2, 
ЖИВОСЛАВ Љ. ТЕШИЋ1, ALEXANDER ROLLER3 и BERNHARD K. KEPPLER3  
1Hemijski Fakultet,Univerzitet u Beogradu, Studentski trg 12–16, 11 000 Beograd, 2Institut za 
onkologiju i radiologiju Srbije, Pasterova 14, 11000 Beograd i 3Institute of Inorganic Chemistry, 
University of Vienna, Währinger Str. 42, 1090 Vienna, Austria 
Рутенијум(II)–аренски комплекс са пиколинском киселином [(η6-p-цимен)RuCl(пико-
линато)]·H2О синтетисан је у реакцији [(η6-p-цимен)RuCl2]2 комплекса са пиколинском 
киселином у молском односу 1:2 у изопропанолу. Једињење је окарактерисано елементалном 
анализом, ИЦ и NMR спектроскопијом. Анализа дифракцијом X-зрацима показала је да мо-
лекул има тзв. “three-leg piano-stool” геометрију која је карактеристична за овај тип 
комплекса. Цитотоксична активност комплекса је одређена на две хумане туморске ћелијске 
линије, HeLa (грлића материце) и FemX (меланома), МТТ тестом. IC50 вредности су биле 
82,0 и 36,2 µmol dm-3 за HeLa и FemX ћелије, редом. 
(Примљено 17. маја, ревидирано 17. августа 2010) 
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